ED
ARRY

Exane Derivatives’s Array Biopharma Inc ARRY Stock Holding History

Exane Derivatives’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,763
Closed -$39.4K – 726
2018
Q4 		$39.4K Buy
+2,763
New +$41.9K 0.01% 381

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Exane Derivatives's ARRY Position: Q1 2019 in Review

Exane Derivatives sold out of Array Biopharma Inc (ARRY) in Q1 2019, closing a stake of 2,763 shares — an estimated $39.4K sold.

Exane Derivatives first reported a position in ARRY in Q4 2018 and held it in 1 quarter. The position peaked at $39.4K in Q4 2018. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

  • Exane Derivatives reported no remaining Array Biopharma Inc position as of Q1 2019 after selling out during the quarter.
  • Exane Derivatives sold 2,763 Array Biopharma Inc shares in Q1 2019, an estimated $39.4K.
  • Exane Derivatives first reported a position in Array Biopharma Inc in Q4 2018 and held it in 1 quarter.
  • Exane Derivatives's Array Biopharma Inc position peaked at $39.4K in Q4 2018.
  • 268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on Exane Derivatives's 13F filing for Q1 2019, filed 24 Apr 2019.